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Pharmacists have the opportunity 
to develop strategies in order to 
circumvent drug shortages ensuring 
appropriate patient outcomes. 
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Introduction 
A drug shortage is an inadequate supply of medication that negatively affects how a pharmacy dispenses, compounds or clinically 
uses a drug, as defined by the American Journal of Health-System Pharmacy. Drug shortages in the U.S. health care system are 
more prevalent now than ever, and their impact is very substantial. In 2010, there were 178 reported drug shortages, up from 61 in 
2005 according the Federal Drug Administration (FDA) Center for Drug Evaluation and Research (CDER). 1 Our health care system is 
designed to rely on the availability of safe, effective and cost-efficient medications. When a medication is unavailable, there are 
significant consequences not only in the quality of care offered to patients but also in the economic viability of such services. Un-
derstanding the causes, challenges and impacts of drug shortages can help pharmacists effectively manage this problem. Pharma-
cists have the opportunity to develop strategies in order to circumvent drug shortages ensuring appropriate patient outcomes. In 
order for a pharmacist to effectively manage drug shortages, the pharmacist must first understand the causes as well as the impact 
on patient care, economical effects and enhanced professional responsibilities of this prevalent problem. 
Why do Drug Shortages Exist? 
Due to the innate complexity of pharmaceutical supply chains, often it 
is very difficult to pinpoint a reason for a drug shortage. There are 
many factors that go into the production and distribution of a drug, 
and a disturbance at any phase may result in a drug shortage. A drug 
shortage may be the result of insufficient raw materials and may take 
over a year for a manufacturer to locate a new source of material and 
obtain FDA approval. 2 More than 80 percent of raw materials are im-
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ing. Besides problems with raw materials, a manufacturer may discon-
tinue production of a drug strictly for financial reasons. For example, if a drug does not achieve a certain profit margin, a pharma-
ceutical manufacturer may elect to stop its production. As a result, other manufacturers are left responsible to meet the demand 
of the product. Due to antitrust laws, a manufacturer is not permitted to notify competitors before discontinuing a product. The 
manufacturer does, however, have the ability to notify the FDA if they choose. The FDA will then post information to the public. 
Informing the FDA is not required unless the company is the sole manufacturer of a life-saving drug. In short, the FDA has no au-
thority to require a manufacturer to make a product. Also, FDA regulation is a major cause of drug shortages. A manufacturer must 
meet good manufacturing practice (GMP) regulations. If a manufacturer fails to meet these regulations, the FDA will provide the 
manufacturer with a list of problems and potential corrective actions that need to be taken. Upon subsequent inspections from the 
FDA, if the manufacturer did not correct the problems, the FDA may take enforcement action . This could lead to the shutdown of 
manufacturing sites. Furthermore, manufacturers may choose to voluntarily recall a product due to production issues thus leading 
to temporary shortages. Although preservation of the availability of a drug is always attempted, sometimes it is just not possible. 2 
How are Drug Shortages Handled? 
... ... Both manufacturers and health care systems have a large role in drug shortages and availability. For 
example, manufacturers commonly employ a just-in-time inventory management style due to the lack of 
available resources. As a result, when a drug shortage arises, manufacturers are unable to meet the 
increased demand. Similarly, many hospitals also employ the just-in-time inventory management style. 
However, an institution aims to maximize profits by reducing the cost of inventory. During a drug shortage, 
the small amount of inventory on hand will result in the unavailability of a medication to patients. 1 
For example, in March 2011, the FDA issued a bulletin regarding the drug shortage of calcium gluconate. Due to the calcium chloride 
shortage resulting from American Regent, Inc. ceasing its production seven months prior, an increased demand of the therapeutic 
alternative, calcium gluconate arose. Furthering the gluconate shortage, two other companies were also experiencing manufacturing 
delays with this product. As a result, other manufacturers of calcium gluconate such as APP Pharmaceuticals, LLC and Luitpold Phar-
maceuticals, Inc., experienced an overwhelming demand for this drug starting in June 2011. At the time this article was written, cal-
cium gluconate products were either on backorder, currently being allocated, and/or had been discontinued according to the FDA 
drug shortage list.3 As of now, supplies are being released in limited quantities as they become available. There are many efforts being 
made to conserve this limited supply. First and foremost, health care practitioners began restricting the use of calcium within their 
institutions to the most critically ill patients and those who were experiencing severe symptoms of hypocalcemia. 
There have been several recent examples where supplies of individual medications have been exhausted and health systems were 
forced to look at alternatives. Several approaches are often employed in concert to be sure that safe and effective care is not com-
promised. This usually includes convening content experts to determine criteria for using limited remaining drug supplies and iden-
tifying any alternatives that might be feasible. At the same time, unnecessary use of the medication is prevented through a variety 
of mechanisms that include use of electronic health information systems, provider education and direct pharmacist intervention. In 
the most extreme cases, hospital leadership is involved to determine if elective or other non-urgent procedures or admissions need 
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t o be delayed if sufficient drug supplies are not available to meet the needs of target patient populations. 
What Factors are Impacted? 
The most significant impact of a drug shortage is compromised patient care. The Institution for Safe Medication Practices (ISMP} 
conducted a study in 2010 looking at the consequences of drug shortages on patient safety. Of the 1,800 practitioners that re-
sponded, 35 percent reported that their facility experienced a near miss that could have resulted in patient harm due to a drug 
shortage. Additionally, 25 percent reported that the error actually reached the patient and 20 percent testified that the error re-
sulted in an adverse event.4 With such a high incidence of medication errors related to drug shortages, it is important to under-
stand how shortages compromise patient safety in such a substantial fashion. One of the most common ways to deal with a drug 
shortage is for a physician to prescribe an alternative medication. Many times the physician may not be very familiar with the alter-
native option. As a result, contraindications and dosing regimens may not be fully understood. Also, some alternative medications 
may not be as effective as the first-line therapy. Furthermore, therapeutic alternatives may not exist for certain drugs. All of these 
challenges compromise the care and safety of the patient. 
In addition to having a negative impact on patients, the increased labor brought about by drug shortages cannot be ignored. A sur-
vey was conducted that included 353 directors of pharmacy from across the nation. It was found that pharmacist and pharmacy 
t echnicians spend a considerable amount of time (pharmacist: 9 hours/week, pharmacy technician: 8 hours/week} managing drug 
shortages as compared to other health care professionals (physicians: 0.5 hours/week, nurses: 0 hours/week}. 5 This statistic is 
considerably higher than in 2004 when pharmacists spent 3 hr/wk managing drug shortages. This increased burden results in phar-
macists having less time for other high value tasks such as medication therapy management, direct patient care, and enhanced 
drug delivery. Another very large contributor to increased labor is the extensive use of automation systems in most institutions. 
Frequently automation systems such as electronic physician ordering, barcode technology, and inventory systems are used in con-
junction with one another. Although the increasing use of automation is beneficial within the realm of normal operations, the pres-
ence of a drug shortage can cause significant problems. The integration of a new drug and/or protocol into an automated system 
requires an extensive amount of human resources.6 In contrast, a hospital with a more manual ordering system may present with 
other challenges such as notifying prescribers of a drug shortage at the time of prescribing. 
Not only do drug shortages have a significant impact on patient care and safety, but they have a substantial impact economically as 
well. As mentioned, one of the most prevalent ways to deal with a drug shortage is through the use of alternative medications. 
Typically if an institution is able to purchase an alternative generic, it is attained at an increased cost due to off-contract pricing. A 
recent study estimated that the purchase of more expensive generics and therapeutic alternatives is at least $200 million annually. 
When this considerable cost is combined with the $216 million associated with increased labor cost5, the extensive economic im-
pact of drug shortages becomes very clear. 
The Role of the FDA 
As discussed, drug shortages are more prevalent and severe in 
today's society. Not only do they compromise patient safety, but 
they increase the workload of the pharmacy staff and have a sub-
stantial economic impact. Due to the severity of these conse-
quences, the FDA works to minimize the effects of drug short-
ages. When a product that is considered a medical necessity be-
comes unavailable, the FDA follows a series of steps within the 
CDER to help resolve the situation. A medical necessity, as de-
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is a medication that "is used to treat or prevent a serious disease ... or condition, and there is no other available source of that prod-
uct...[or] an adequate substitute."1 Cost and inconvenience to the manufacturer and/or patient does not qualify the substance as a 
medical necessity. Therefore, if a drug is considered a medical necessity, the FDA will work with pharmaceutical manufacturers to 
help acquire additional raw material, technology, or machinery needed to produce the medication. Although the FDA cannot re-
quire companies to increase production, it can expedite the review of manufacturing practices. 7 This could include extending the 
product's expiration date, licensing distributors or using materials from different sources. More specifically, if a medication is avail-
able but is not identical to the needed product, the FDA can conduct a health hazard evaluation to determine the drug's risk pro-
file.8 Based on these findings, the drug may be used in some protocols. In severe drug shortage cases, the FDA has the authority to 
temporarily allow the import of non-FDA approved therapy equivalents.9 Throughout these practices, however, maintaining patient 
safety is of upmost importance. The federal government is taking steps to regulate drug shortages as evidenced by the Executive 
Order on Reducing Prescription Drug Shortages, which was ordered by President Barack Obama on October 31, 2011. 10 
Along with collaborating with manufacturers, the FDA also provides continuous updates to the community about the shortage. In 
1999, the FDA created the Drug Shortage Program (DSP} as part of the CDER. One of the components of this program is to act as a 
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liaison between health care professional organizations and manufacturing companies. 7 Working closely with pharmaceutical dis-
tributors allows the FDA to provide accurate and timely information to patient groups. Therefore, if a manufacturer decides to dis-
continue a product and eventually cause a shortage, the FDA can notify important stakeholders and prepare accordingly. As a re-
sult, health care professionals are able to identify other treatments for their patients. However, there are additional considerations 
when utilizing alternative medications. Higher risk profiles, sub-therapeutic results and adverse events are only a couple of exam-
ples. Nonetheless, the FDA's open communication allows health care organizations adequate time to prepare for a drug shortage. 
ASHP Guidelines 
American Society of Health-System Pharmacists (ASHP) developed guidelines for health care professionals, specifically pharmacists, 
to use when faced with a drug shortage. 11 These guidelines are divided into a process that has three main phases: the assessment 
phase, the preparation phase and the contingency phase. It is important to note that pharmacists have a vital role in each of these 
phases. 
Throughout the first phase (assessment phase) the duration of the shortage must be determined. Depending on the length of the 
shortage, institutions may respond differently to the situation. For example, a lack of raw material may cause multiple manufactur-
ers to be unable to produce a drug. As a result, pharmacy and therapeutic committees must find a therapeutic alternative. Before 
beginning the preparation phase, it is also important for institutions to determine the amount of medication on hand. Based on the 
quantity and usage history, a measurement of how long a shortage can be endured can be determined. 11 
In order to maintain optimal patient care, the second phase (preparation phase) is vital for pharmacists to utilize in the manage-
ment of drug shortages. This phase involves preparing for a shortage before its effects are actually seen. For instance, a medication 
substitution must be considered. Since pharmacists are the drug experts, they have a crucial role in selecting the most ideal alter-
native. Though a pharmacist should lead this selection, collaborating with doctors, nurses and residents is crucial. While determin-
ing drug alternatives, patient safety must also not be forgotten. Therefore, pharmacists are responsible for implementing plans for 
medical professionals so that patient safety is not compromised. Finally, during the preparation phase, other supply sources of the 
drug must be researched. If located, availability, contract agreements and payment terms should be discussed. It is crucial for phar-
macists not to stockpile a medication. This could lead to a misidentified drug shortage and reduce patient care. 11 
The last and third phase (contingency phase) encompasses therapies that are nontraditional. These medications do not have any 
therapeutic alternatives nor can they be prepared by a traditional manufacturer. When this happens, institutions should work 
closely with the FDA. Pharmacists can counsel patients and their families if a delay or compromise in care will occur. Additionally, 
communicating with the media and other health care organizations can raise awareness of the shortage. As a result, nontraditional 
companies that produce the drug may be discovered or manufacturers may be motivated to formulate the medication. Throughout 
the three phases outlined by ASHP, pharmacists have an integral role. From communication advantages to determining therapeutic 
alternatives, utilization of pharmacist knowledge is vital when faced with a drug shortage. 11 
Conclusion 
Understanding the contributing factors and consequences of drug shortages is critical for a pharmacist to provide optimal patient 
care. This is especially important in today's society due to the fact that drug shortages have reached an all time high. Though the 
causes of shortages are complex, some contributing factors are lack of resources and manufacturing regulations. One of the major 
implications of drug shortages is increased labor forthe pharmacy staff. As a result, both patient care and health system economics 
are compromised. Fortunately, the FDA has a major role in preventing, regulating and promoting awareness of drug shortages. 
Despite the FDA's efforts, the ultimate responsibility of managing drug shortages falls upon the pharmacist. By applying the phase 
model created by ASHP, a pharmacist can effectively manage this prevalent problem. 
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